WallStSmart

Axogen Inc (AXGN)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 14803% more annual revenue ($35.48B vs $238.10M). MDT leads profitability with a 13.0% profit margin vs -13.2%. MDT appears more attractively valued with a PEG of 1.29. MDT earns a higher WallStSmart Score of 61/100 (C+).

AXGN

Avoid

30

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 0.32

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AXGN.

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXGN2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
26.6%8/10

Revenue surging 26.6% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

AXGN4 concerns · Avg: 3.3/10
Price/BookValuation
9.3x4/10

Trading at 9.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
99.042/10

Expensive relative to growth rate

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : AXGN

The strongest argument for AXGN centers on Debt/Equity, Revenue Growth. Revenue growth of 26.6% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bear Case : AXGN

The primary concerns for AXGN are Price/Book, EPS Growth, Piotroski F-Score.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

AXGN profiles as a growth stock while MDT is a value play — different risk/reward profiles.

AXGN carries more volatility with a beta of 1.17 — expect wider price swings.

AXGN is growing revenue faster at 26.6% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axogen Inc

HEALTHCARE · MEDICAL DEVICES · USA

AxoGen, Inc., develops and markets surgical solutions for physical damage or transection of peripheral nerves. The company is headquartered in Alachua, Florida.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?